Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:

“Myeloma Paper of the Day: Genomic profiling of high-risk SMM patients who got intensive treatment shows DIS3, FAM46C, FGFR3 mutations, t(4;14) and 1q alterations enriched in HR SMM, NRAS mutations and co-occurrence t(4;14)/FGFR3 mutations associated with increased progression.”

Proceed to the article.
Source: Robert Orlowski/X